Navigation Links
Beckman Coulter Announces Third Quarter 2009 Results
Date:10/29/2009

rotect the company's intellectual property; difficulty in obtaining materials and components for our products; consolidation of our customer base, formation of group purchasing organizations and changes in customer inventory levels and inventory management practices; reductions in government funding to our customers; foreign currency exchange fluctuations; global market, economic and political conditions and natural disasters; costs associated with our supply chain initiatives; tax risks and regulations; changes in the value of our investment in marketable securities; and our ability to successfully acquire and integrate acquired businesses and realize the anticipated benefits from such acquisitions. Additional factors that could cause actual results to differ are discussed in Part I, Item 1A (Risk Factors) of the company's Form 10-K filed with the SEC on February 23, 2009 as well as in the company's Form 10-Q filed since then and reports on Form 8-K. Forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update these disclosures except as required by law.

Change in Accounting for Convertible Debt Securities

In May 2008, the FASB issued a new accounting standard related to convertible debt instruments that may be settled in cash upon conversion. Under this standard, such convertible debt securities would be separated into a debt and equity component. This change in principle, which was effective for us as of January 1, 2009, was applied retrospectively to previously issued convertible debt instruments. The adoption of this new accounting standard increased our 2008 and 2007 non-cash interest expense by approximately $13 million per year, resulting in a reduction of our diluted earnings per share by approximately $0.12 in 2008 and 2007. Interest expense increased by $3.6 million and $3.5 million for the three months ended September 30, 2009 and 2008, respectiv
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Low birth weight, less breastfeeding create later health risks 2
... YORK, March 7 The following statement is,from Hughes ... Cotlar, LLP:, United States District Judge Eldon E. ... and Deputy Special Masters who will decide,any appeals taken ... resolution program for Vioxx product liability litigation in the,United ...
... has named 13 translational researchers as the 2008 ... Research. The awards, which provide $150,000 per ... support established, independent physician-scientists who are dedicated to ... patient treatmentand mentoring physician-scientist trainees. , The ...
... March 7 Duane Reade Holdings, Inc. today,announced that ... fourth,quarter and full year 2007 financial results before the ... release, the Company will hold a conference,call on Thursday, ... Interim Chief Executive Officer and Chief Marketing Officer, and,John ...
... Tenn., March 7 HCA Inc. announced today the,final results ... million of,its debt securities specified in the table below. The ... 6, 2008. The tender offer was,made on the terms and ... dated February 7, 2008 and the related Letter of Transmittal., ...
... UC Irvine researchers have discovered a dramatically improved method ... easier for scientists to study and potentially treat thousands ... and diabetes. , The technique for the first time ... rates and increase the efficiency of inserting DNA into ...
... TEMECULA, Calif., March 7 Raintree Systems, ... practice management,and electronic medical records solutions, releases ... medical record product for,Bariatric Surgery., The ... for a,single center and enterprise-level implementations; thus ...
Cached Medicine News:Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 2Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 4Health News:Burroughs Wellcome Fund grants $9.75 million towards translational researchers 2Health News:HCA Announces Final Results for its Debt Tender Offer 2Health News:HCA Announces Final Results for its Debt Tender Offer 3Health News:HCA Announces Final Results for its Debt Tender Offer 4Health News:New stem cell technique improves genetic alteration 2Health News:New stem cell technique improves genetic alteration 3Health News:Raintree Systems Launches the First Integrated Practice Management and Electronic Medical Records Application Within the Bariatric Surgery Industry 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: